Skip to main content
MSLE
NASDAQ Life Sciences

Satellos Gets FDA Clearance to Test Forazapadin in FSHD, Secures $5M Non-Dilutive Funding

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$8.91
Mkt Cap
$178.43M
52W Low
$5.44
52W High
$144
52W Position info
64% above low
Off High info
94% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MSLE sits 64% above its 52-week low of $5.44.

Summary

FDA cleared Satellos' IND for forazapadin in FSHD, its second indication, and the FSHD Canada Foundation will provide up to US$5 million in non-dilutive funding. A Phase 2 FSHD study is planned for Q4 2026.


Key Events · Product Development and Regulatory · MSLE

  • FDA Clears IND for FSHD

    FDA cleared the Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD), the second indication for the drug candidate.

  • Non-Dilutive Financing Secured

    FSHD Canada Foundation will provide up to US$5 million in milestone payments over five quarters in exchange for a capped revenue-sharing interest in future FSHD-related proceeds.

  • Phase 2 Study Planned for Q4 2026

    A randomized, double-blind, placebo-controlled Phase 2 study will evaluate 60 mg and 120 mg doses of forazapadin in adults with FSHD, with initiation expected in Q4 2026.

  • Expands Muscle Regeneration Franchise

    Forazapadin is already in Phase 2 trials for Duchenne muscular dystrophy (DMD); this FSHD clearance broadens the company's pipeline into a second degenerative muscle disease with no approved therapies.


Analysis · MSLE · Life Sciences

Satellos expands its lead drug candidate into a second muscular dystrophy indication with FDA clearance of its IND for FSHD, a disease with no approved therapies affecting an estimated 800,000 people worldwide. The company also secured up to US$5 million in non-dilutive financing from the FSHD Canada Foundation, extending its cash runway without shareholder dilution. A Phase 2 proof-of-concept study is expected to start in Q4 2026, testing two dose levels of forazapadin. This builds on positive interim DMD data reported in July and positions the company to pursue a broader muscle-regeneration franchise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MSLE was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $178.4M. The 52-week trading range was $5.44 to $144.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MSLE - Latest Insights

MSLE
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.88
Real-time Price: $5.71 info
Change: -$1.17 (-17%) info
Market Cap: $123.055M info
MSLE
Nov 06, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $6.00
Real-time Price: $5.71 info
Change: -$0.290 (-5%) info
Market Cap: $123.055M info
MSLE
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.60
Real-time Price: $5.71 info
Change: -$2.89 (-34%) info
Market Cap: $123.055M info
MSLE
Aug 13, 2026, 5:03 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.82
Real-time Price: $5.71 info
Change: -$4.11 (-42%) info
Market Cap: $123.055M info
MSLE
Jul 08, 2026, 6:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.37
Real-time Price: $5.71 info
Change: -$2.66 (-32%) info
Market Cap: $123.055M info